anti thbs1 (Bio-Techne corporation)
Structured Review

Anti Thbs1, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti thbs1/product/Bio-Techne corporation
Average 94 stars, based on 13 article reviews
Images
1) Product Images from "Doxorubicin-induced cardiovascular toxicity: a longitudinal evaluation of functional and molecular markers"
Article Title: Doxorubicin-induced cardiovascular toxicity: a longitudinal evaluation of functional and molecular markers
Journal: Cardiovascular Research
doi: 10.1093/cvr/cvad136
Figure Legend Snippet: Proteomic analysis of aortic samples from DOX-treated mice at Weeks 2 and 6 and validation of two candidate biomarkers with western blotting. Plots of differentially expressed proteins at Weeks 2 and 6 ( A ). For A , horizontal grey line indicates significance threshold ( P < 0.05); up- and down-regulated proteins are indicated in blue and red, respectively; differentially expressed proteins are abbreviated (full names are listed in abbreviations list). Western blotting shows and corroborates higher levels of SERPINA3 in DOX-treated mice at Weeks 2 and 6, which persist at Week 9 ( B ). Western blotting also confirms higher levels of THBS1 in the DOX-treated group at Weeks 2 and 6 and shows a trend ( P = 0.052) towards increased THBS1 levels at Week 9 ( B ). Representative western blot images for SERPINA3 and THBS1 at Weeks 2, 6, and 9 ( C ). For C , ‘V’ and ‘D’ indicate lanes with vehicle and DOX aortic samples, respectively. D* on the blot at Week 9 contains a DOX sample for which no protein was detected and was excluded from analysis as such. For A , n = 8 in vehicle and DOX group for both Week 2 and Week 6. For B , vehicle group: n = 5, n = 6, and n = 6 at Weeks 2, 6, and 9, respectively; DOX group: n = 5, n = 6, and n = 5 at Weeks 2, 6, and 9, respectively. For B , Mann–Whitney U test for each time point. * and ** P < 0.05 and 0.01. Abbreviations for differentially expressed proteins in proteomics: SERPINA1E, α-1-antitrypsin; HMGN2, Non-histone chromosomal protein HMG-17; SERPINA3N, α-1-antichymotrypsin orthologue n; MT2, Metallothionein-2; MBL2, Mannose-binding protein C; MT1, Metallothionein-1; THBS1, Thrombospondin-1; FTL1, Ferritin light chain 1; COL14A1, Collagen α-1 (XIV) chain; LGALS3BP, Galectin-3-binding protein; RPL26, 60S ribosomal protein L26; IGHM, Immunoglobulin heavy constant µ; HAMP, Hepcidin; APOA2, Apolipoprotein A-II; HBA, Hemoglobin subunit α; HBB-B1, Hemoglobin subunit β-1; CA1, Carbonic anhydrase 1; KRT15, Keratin (type I cytoskeletal 15); SPTA1, Spectrin α; CA2; Carbonic anhydrase 2; RPL6, 60S ribosomal protein L6; VWA1, von Willebrand factor A domain-containing protein 1; RPL37A, 60S ribosomal protein L37a; CAPG, Macrophage-capping protein; RAD23A, UV excision repair protein RAD23 homolog A; IGHG1, Ig γ-1 chain C region (membrane-bound form); SLC4A1, Band 3 anion transport protein; ACLY, ATP-citrate synthase; ATPA1, Sodium/potassium-transporting ATPase subunit alpha-1.
Techniques Used: Western Blot, MANN-WHITNEY, Binding Assay, Membrane
Figure Legend Snippet: Quantification of SERPINA3 and THBS1 levels in plasma of control and AICT patients using ELISA. Schematic overview of the patient cohorts ( A ). AICT patients exhibited higher SERPINA3 and THBS1 levels compared with the control group ( B ). Both SERPINA3 and THBS1 showed an inverse Pearson correlation with LVEF ( C ). For B , data are presented as Tukey box plots with median (horizontal line) and the 25th and 75th percentile whiskers. For C , white and red dots represent control and AICT patients, respectively. n numbers are shown in A . For B , Mann–Whitney U test. * and **** P < 0.05 and 0.0001.
Techniques Used: Enzyme-linked Immunosorbent Assay, MANN-WHITNEY
